Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study

MLA

Sungrae Kim, and Sang Yong Kim. “Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-Interventional, Single-Arm, Open-Label, Multicenter Observational Study.” Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, Oct. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0660423e84d20e6f65a83e4c3c2c532b&authtype=sso&custid=ns315887.

APA

Sungrae Kim, & Sang Yong Kim. (2022). Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders.

Chicago

Sungrae Kim, and Sang Yong Kim. 2022. “Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-Interventional, Single-Arm, Open-Label, Multicenter Observational Study.” Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, October. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0660423e84d20e6f65a83e4c3c2c532b&authtype=sso&custid=ns315887.